Literature DB >> 7734308

Deoxythymidine kinase in the tumour cells and serum of patients with non-Hodgkin lymphomas.

S Rehn1, J S Gronowitz, C Källander, C Sundström, B Glimelius.   

Abstract

The levels of deoxythymidine kinase in tumour cells (C-TK) and in serum (S-TK) were investigated and the tumour volume calculated in 89 patients with non-Hodgkin lymphoma (NHL), in order to ascertain the importance of C-TK and tumour burden as regards the S-TK levels. Among all patients, a correlation was seen between S-TK and tumour volume but not between S-TK and C-TK. However, within different tumour volume categories (small, medium-sized and large), there was a correlation between S-TK and C-TK. Multiple regression analysis supported this notion. C-TK correlated with the proliferation-associated parameters, S-phase fraction and mitotic index. As already known, S-TK was found to have a strong prognostic value. C-TK and tumour burden were also of prognostic value. In multivariate analyses, C-TK and tumour volume did not provide prognostic information in addition to S-TK, whereas, in the absence of S-TK, C-TK and tumour volume did provide additional information. It is concluded that the serum level of TK depends on both the tumour burden and the tumour cell proliferation rate. Based upon estimations of S-TK in patients assessed shortly after chemotherapy, we also suggest that S-TK reflects the number of proliferating cells that have died during the period immediately before sampling.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7734308      PMCID: PMC2033808          DOI: 10.1038/bjc.1995.213

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  37 in total

1.  Thymidine kinase activity in the human bone marrow from various blood diseases.

Authors:  K Nakao; S Fujioka
Journal:  Life Sci       Date:  1968-04-15       Impact factor: 5.037

2.  Prognostic relevance of thymidine kinase isozymes in adult non-Hodgkin's lymphoma.

Authors:  P H Ellims; T Eng Gan; G Medley; M B Van Der Weyden
Journal:  Blood       Date:  1981-11       Impact factor: 22.113

3.  Pyrimidine and purine activities in non-Hodgkin's lymphoma. Correlation with histological status and survival.

Authors:  T E Gan; P D Finch; J L Brumley; L J Hallam; M B van der Weyden
Journal:  Eur J Cancer Clin Oncol       Date:  1984-03

4.  Serum thymidine kinase in monoclonal gammopathies. A prospective study. The Cooperative Group for Study and Treatment of Multiple Myeloma.

Authors:  R Luoni; G Ucci; A Riccardi; P Gobbi; F M Avato; C Vignale; E Ascari
Journal:  Cancer       Date:  1992-03-15       Impact factor: 6.860

5.  Application of an in vitro assay for serum thymidine kinase: results on viral disease and malignancies in humans.

Authors:  J S Gronowitz; F R Källander; H Diderholm; H Hagberg; U Pettersson
Journal:  Int J Cancer       Date:  1984-01-15       Impact factor: 7.396

6.  Serum thymidine kinase in vitamin B12 deficiency.

Authors:  H Hagberg; S Gronowitz; A Killander; C Källander
Journal:  Scand J Haematol       Date:  1984-01

7.  Serum thymidine kinase in acute leukaemia.

Authors:  H Hagberg; S Gronowitz; A Killander; C Källander; B Simonsson; C Sundström; G Oberg
Journal:  Br J Cancer       Date:  1984-04       Impact factor: 7.640

8.  The use of serum deoxythymidine kinase as a prognostic marker, and in the monitoring of patients with non-Hodgkin's lymphoma.

Authors:  J S Gronowitz; H Hagberg; C F Källander; B Simonsson
Journal:  Br J Cancer       Date:  1983-04       Impact factor: 7.640

9.  Prognostic factors in non-Hodgkin's lymphoma: the importance of symptomatic stage as an adjunct to the Kiel histopathological classification.

Authors:  R C Leonard; J Cuzick; I C MacLennan; R I Vanhegan; P H Mackie; C V McCormick
Journal:  Br J Cancer       Date:  1983-01       Impact factor: 7.640

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1976-12       Impact factor: 7.640

View more
  2 in total

1.  Evaluation of serum thymidine kinase 1 activity as a biomarker for treatment effectiveness and prediction of relapse in dogs with non-Hodgkin lymphoma.

Authors:  Pierre Boyé; Franck Floch; François Serres; Kévyn Geeraert; Pierre Clerson; Xavier Siomboing; Mattias Bergqvist; Gabriel Sack; Dominique Tierny
Journal:  J Vet Intern Med       Date:  2019-05-25       Impact factor: 3.333

2.  Thymidine Kinase Type 1 and C-Reactive Protein Concentrations in Dogs with Spontaneously Occurring Cancer.

Authors:  K A Selting; R Ringold; B Husbands; P O Pithua
Journal:  J Vet Intern Med       Date:  2016-05-23       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.